Hematology

Two Treatment Philosophies Shape the Sickle Cell Pipeline: One-Time Gene Therapy Versus Daily Oral Medicine

The sickle cell disease treatment pipeline is bifurcated between potentially curative one-time gene therapies and chronic oral disease-modifying medicines. Hematologists express enthusiasm for both approaches, recognizing the distinct benefits and challenges each offers patients.